Evinova China and Harbour BioMed Announce Strategic AI Collaboration to Accelerate AI-Enabled Drug Development
Yesterday, during the 8th China International Import Expo (“CIIE”), Evinova, a global health-tech company accelerating the delivery of better health outcomes by propelling the life sciences sector forward in digital health, and Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, announced a strategic collaboration in artificial intelligence (AI).
Evinova Reveals Key Findings on Digital Tool Adoption Among Investigative Sites
A new study conducted by the Tufts Center for the Study of Drug Development (Tufts CSDD) and supported by Evinova, a global clinical trial technology company with proven published outcomes for sponsors, sites and patients, reveals that investigative sites are increasingly adopting and self-investing in digital tools to support the conduct of clinical research.
Evinova and Quantum Leap Healthcare Partner to Incorporate Real-Time Remote Patient Monitoring into Breast Cancer Platform Trial
Evinova, a global clinical trial technology company with proven published outcomes for sponsors, sites and patients, announced today an agreement with Quantum Leap Healthcare Collaborative™ (QLHC) to incorporate Evinova’s remote patient monitoring (RPM) solution into I-SPY 2.2. I-SPY 2.2 is the largest and longest-running 'platform' trial that provides a framework to study multiple novel therapeutic treatment arms for women with newly diagnosed, locally advanced breast cancer. Evinova’s RPM module will be used to alert healthcare professionals of early symptoms of interstitial lung disease (ILD), a potential adverse event for one treatment arm in the study.
